Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100.

Authors

Joaquim Bellmunt

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Joaquim Bellmunt , Thomas Powles , Miguel Angel Climent Duran , Srikala S. Sridhar , Howard Gurney , Nuno Costa , Alessandra Di Pietro , Bo Huang , Shilpa Gupta , Petros Grivas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.

First Author: Begoña Pérez-Valderrama

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

First Author: Petros Grivas

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.

First Author: Yohann Loriot

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.

First Author: Srikala S. Sridhar